HC Wainwright restated their neutral rating on shares of Carisma Therapeutics (NASDAQ:CARM – Free Report) in a report released on Monday, Marketbeat Ratings reports.
Several other brokerages have also recently commented on CARM. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. D. Boral Capital lowered their price objective on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, December 9th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Finally, EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Carisma Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.94.
Check Out Our Latest Stock Report on Carisma Therapeutics
Carisma Therapeutics Stock Performance
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, sell-side analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.
Institutional Trading of Carisma Therapeutics
Several large investors have recently made changes to their positions in CARM. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics in the second quarter valued at about $40,000. Vanguard Group Inc. raised its stake in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after acquiring an additional 11,200 shares during the last quarter. Wexford Capital LP lifted its position in shares of Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the last quarter. Institutional investors own 44.27% of the company’s stock.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.
See Also
- Five stocks we like better than Carisma Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Upcoming IPO Stock Lockup Period, Explained
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.